UNICANCER
267
49
98
124
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
8.2%
22 terminated/withdrawn out of 267 trials
84.9%
-1.7% vs industry average
32%
85 trials in Phase 3/4
6%
7 of 124 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (267)
Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
Role: collaborator
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
Role: collaborator
Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
Role: lead
Immunotherapy Master Trial for Advanced Cancers
Role: lead
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Role: lead
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients
Role: lead
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels
Role: lead
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Role: lead
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
Role: lead
Tracking Triple-negative Breast Cancer Evolution Through Therapy
Role: lead
Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome
Role: lead
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
Role: lead
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
Role: lead
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Role: lead
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
Role: lead
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
Role: lead
QUALIOR Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program
Role: lead
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
Role: lead
Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.
Role: lead
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)
Role: lead